Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group

详细信息    查看全文

• 作者：Samantha C. Sodergren^a ; ^{S.C.Sodergren@soton.ac.uk" class="auth_mail}Author Vitae ; Alice White^a ; Fabio Efficace^b ; Mirjam Sprangers^c ; Deborah Fitzsimmons^d ; Andrew Bottomley^e ; Colin D. Johnson^a
• 关键词：Gastrointestinal stromal tumour ; Tyrosine kinase inhibitors ; Imatinib ; Sunitinib ; Side effects ; Symptoms
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：July 2014
• 年：2014
• 卷：91
• 期：1
• 页码：35-46
• 全文大小：664 K

文摘

Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of advanced gastrointestinal stromal tumours (GISTs). Imatinib is approved as first line therapy and sunitinib is used in cases of imatinib resistance or intolerance. Compared with conventional treatments, TKIs are delivered over longer periods of time and are more specific in their targets (i.e., molecularly targeted), thus presenting different side effect profiles. We review the safety profiles of imatinib and sunitinib, documenting a total of 95 side effects including patient based as well as medically defined outcomes. Gastrointestinal complaints, particularly diarrhoea and nausea, oedema, fatigue and haematological disorders, notably anaemia, are amongst the most prevalent side effects. While there is overlap between the side effect profiles of imatinib and sunitinib, important differences emerge in the frequencies of oedema, hypertension, thyroid functioning, muscle and joint pains, as well as skin and oral conditions. Awareness of potential side effects is informative to both clinician and patient in terms of treatment decision making and can have important implications for treatment adherence and clinical outcome.